Program
Daxokafusp Alfa
In Sanofi's pipeline, PD1xIL15 fusion protein
. Its studies are mostly in Stomach Neoplasms, led by Sanofi.
Furthest: phase 2, since Oct 7, 20222 company-led studies, 2 open or runningNext primary completion: Jan 19, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 22 open or running | phase 2since Oct 7, 2022 | Oct 7, 2022 | Jan 19, 2027phase 2 · NCT05584670 |
- Named in Sanofi’s own pipeline as
SAR445877
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2022First study: phase 2 study in Solid TumorFirst studyNCT05584670 · 542 planned · United States, Chile, Israel and more
- Jun 24, 2026Phase 2 study in Stomach NeoplasmsNCT07692204 · 30 planned · China
Ahead
- Jan 19, 2027Primary completion: phase 2 study in Solid TumorNCT05584670
- Aug 2, 2028Primary completion: phase 2 study in Stomach NeoplasmsNCT07692204
TargetBeta
“PD1xIL15 fusion protein”the company's pipeline, read by Claude · source
“A fusion protein composed of an antibody moiety targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the immunostimulatory cytokine interleukin-15 (IL-15), with potential immune checkpoint inhibitory, immunomodulatin…”NCIt, read by Claude
“A fusion protein composed of an antibody moiety targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07692204Stomach Neoplasms · China | 2 | Recruiting | Aug 2, 2028 | 30 |
| NCT05584670Solid Tumor · United States, Chile, Israel and more | 2 | Recruiting | Jan 19, 2027 | 542 |
How it is read
Names in the registry
- “SAR445877”, 2 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.